InGel Therapeutics is Harvard-spinoff, regenerative medicine biotech leveraging novel neuroprotective mechanisms to stop retinal degeneration. Our beachhead indication is Retinitis Pigmentosa, with future expansion opportunities which include Dry-AMD and Glaucoma.
